[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Second Affiliated Hospital of Hainan Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":142},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,71,99,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100634953","a-study-investigating-the-efficacy-and-safety-of-the-combination-of-iparomlimab-and-tuvonralimab-with-or-without-chemotherapy-in-second-line-and-subsequent-treatments-for-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-100634953",false,"NCT07546383","A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Sign a written informed consent form before any trial-related procedures are performed；\n2. Ages 18 to 75, regardless of gender；\n3. ECOG performance status of 0-2；\n4. Pathologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck, including the oropharynx, oral cavity, hypopharynx, or larynx；\n5. Has received systemic therapy for recurrent or metastatic HNSCC；\n6. Expected survival time \\> 3 months；\n7. At least one measurable lesion according to the RECIST 1.1 criteria\n8. All acute toxicities resulting from prior anticancer therapy must have resolved to Grade 0-1 (according to NCI CTCAE Version 5.0) or to a level acceptable under the inclusion\u002Fexclusion criteria；\n9. Total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within the normal range. (These levels may be controlled by thyroid replacement therapy.) Asymptomatic subjects with abnormal T3, free T3, or free T4 levels may be enrolled；\n10. Patients must have adequate organ and bone marrow function, and laboratory test results within 7 days prior to grouping must meet the following requirements (conditions must not be met by administering any blood components, cell growth factors, albumin, or other corrective medications within 14 days prior to obtaining the laboratory tests), as follows: 1) Complete blood count (CBC): Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count (PLT) ≥ 75 × 10⁹\u002FL (≥ 50 × 10⁹\u002FL for patients with cirrhosis or splenomegaly); Hemoglobin (HGB) ≥ 90 g\u002FL; 2) Liver function: Serum total bilirubin (TBIL) ≤ 1.5×upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5×ULN; 3) Renal function: Serum creatinine (Cr) ≤ 1.5×ULN or creatinine clearance (CCr) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); Qualitative urine protein ≤ 1+; if qualitative urine protein is ≥ 2+, a 24-hour urine protein quantification test must be performed; if the 24-hour urine protein quantification is \\\u003C 1 g, it is acceptable; Coagulation function: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 2 times the upper limit of normal (ULN).\n\nExclusion Criteria:\n\n1.A confirmed history of other types of cancer unrelated to the target cancer in this study (head and neck squamous cell carcinoma)； 2.Subjects with central nervous system metastases or brain metastases； 3.Patients with acute or chronic active hepatitis B or C; those with hepatitis B virus (HBV) DNA \\> 1,000 IU\u002FmL who have failed antiviral therapy; those with hepatitis C virus (HCV) RNA \\> 10³ copies\u002FmL who have been assessed as unsuitable for immunotherapy; and those who are simultaneously positive for hepatitis B surface antigen (HBsAg) and anti-HCV antibodies； 4.Any life-threatening bleeding episode within the past 3 months, including those requiring blood transfusion, surgery, or local treatment, or ongoing medication； 5.A history of arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or any other serious thromboembolic event. Implantable venous access ports or catheter-related thrombosis, or superficial vein thrombosis, unless the thrombus is stable following conventional anticoagulation therapy. Prophylactic use of low-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg\u002Fday) is permitted； 6.Use of aspirin (\\> 325 mg\u002Fday) or other drugs known to inhibit platelet function, such as dipyridamole or clopidogrel, for 10 consecutive days within 2 weeks prior to the first dose； 7.Symptomatic congestive heart failure (New York Heart Association Class II-IV). Symptomatic or poorly controlled arrhythmias. History of congenital long QT syndrome or a corrected QTc \\> 500 ms on screening (calculated using the Fridericia formula)； 8.A severe bleeding tendency or coagulation disorder, or currently undergoing thrombolytic therapy； 9.A history of gastrointestinal perforation and\u002For fistula within the past 6 months; a history of intestinal obstruction (including partial intestinal obstruction requiring parenteral nutrition); extensive intestinal resection (partial colectomy or extensive small bowel resection complicated by chronic diarrhea); Crohn's disease; ulcerative colitis; or long-term chronic diarrhea； 10.A history of or current pulmonary conditions such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, or severe impairment of lung function； 11.Known history of alcohol abuse, psychotropic substance abuse, or drug use； 12.A history of specific neurological or psychiatric disorders, such as epilepsy, dementia, schizophrenia, etc； 13.Active pulmonary tuberculosis (TB), individuals currently undergoing antituberculosis treatment, or those who received antituberculosis treatment within one year prior to the first dose； 14.Individuals infected with human immunodeficiency virus (HIV) (HIV-1\u002F2 antibody-positive) and individuals with known syphilis； 15.Active severe infections or infections that are not well clinically controlled. Severe infections within 4 weeks prior to the first dose, including but not limited to hospitalization due to complications from infection, bacteremia, or severe pneumonia； 16.Active autoimmune disease requiring systemic treatment (e.g., disease-modifying antirheumatic drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency) is permitted. Known history of primary immunodeficiency. Patients who are only positive for autoimmune antibodies must be evaluated by the investigator to determine whether an autoimmune disease is present； 17.Use of immunosuppressive drugs within 4 weeks prior to the first dose, excluding topical corticosteroids administered via nasal spray, inhalation, or other routes, or systemic corticosteroids at physiological doses (i.e., no more than 10 mg\u002Fday of prednisone or an equivalent dose of other corticosteroids); temporary use of corticosteroids to treat dyspnea associated with conditions such as asthma or chronic obstructive pulmonary disease is permitted； 18.Within 4 weeks prior to the first dose, or if the patient is scheduled to receive an attenuated live vaccine during the study； 19.Major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose, or unhealed wounds, ulcers, or fractures. Tissue biopsy or other minor surgical procedures within 7 days prior to the first dose, excluding venipuncture or catheter placement for the purpose of intravenous infusion； 20.Uncontrolled or uncorrectable metabolic disorders, other non-malignant organ diseases, systemic diseases, or secondary reactions to cancer, which may result in a higher medical risk and\u002For uncertainty regarding survival prognosis； 21.A diagnosis of another malignancy within 5 years prior to the first dose, excluding curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For carcinoma in situ that has been curatively resected. If another malignancy or hepatocellular carcinoma was diagnosed more than 5 years prior to dosing, a pathological or cytological diagnosis of the recurrent or metastatic lesions is required； 22.A history of severe allergic reactions to study drug components (such as the epa-loritovireli combination antibody, platinum agents, docetaxel, or paclitaxel)； 23.Has received treatment in another clinical trial or is currently participating in another clinical study within 4 weeks prior to the first dose； 24.Pregnant or breastfeeding patients； 25.Other acute or chronic medical conditions, psychiatric disorders, or abnormal laboratory test results that may lead to the following: increased risks associated with study participation or administration of the study drug, or interference with the interpretation of study results; and, in the investigator's judgment, render the patient ineligible for participation in this study.\n\n.","ALL","18 Years","75 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of the combination of the antibodies iparomlimab and tuvonralimab, administered with or without chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R\u002FM HNSCC) who have progressed after receiving at least one line of systemic therapy.\n\nThe study includes a safety run-in phase with approximately three patients, which may be expanded to six if a dose-limiting toxicity is observed. Patients are then assigned to either combination antibody monotherapy or combination antibody plus chemotherapy, based on PD-L1 combined positive score (CPS), symptom burden, disease characteristics and patient preference.\n\nMonotherapy involves iparomlimab and tuvonralimab (5 mg\u002Fkg on day 1, every 3 weeks).\n\nCombination therapy involves the same antibody regimen plus up to six cycles of platinum (carboplatin at an area under the curve (AUC) of 5 or cisplatin at 75 mg\u002Fm²) plus docetaxel (75 mg\u002Fm²) or paclitaxel (135-175 mg\u002Fm²), followed by antibody monotherapy maintenance.\n\nThe primary objective is to assess the objective response rate (ORR) according to RECIST 1.1. The secondary objectives are to evaluate the disease control rate (DCR), the 6-month progression-free survival (PFS) rate, the 6-month overall survival (OS) rate and the safety profile. Exploratory objectives include the association of tumour biomarkers (PD-L1 expression and tumour mutation burden) with efficacy.",[26],"Squamous Cell Carcinoma of Head and Neck","RECRUITING","2026-04-16",{"date":30,"type":31},"2026-04-22","ACTUAL",{"date":33,"type":20},"2026-04-13",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"The Second Affiliated Hospital of Hainan Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100634638","phase-2-comparison-of-the-therapeutic-effects-of-methylprednisolone-and-dexamethasone-on-peritumoral-edema-during-radiotherapy-for-brain-metastases-100634638","NCT07542288","Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:","Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:An Adaptive Phase II\u002FIII Seamless Prospective Clinical Study","Inclusion Criteria:\n\n* 1\\. 18 ≤ age ≤ 75 years old, gender not limited, generally acceptable, 40 ≤ KPS ≤ 80 points, the main reason for the patient's limited functional status is related neurological symptoms caused by edema of brain metastases; 2. Confirmed by cranial MRI or CT imaging, there is at least one brain metastasis with cerebral edema or neurological symptoms. All patients are scheduled to undergo WBRT (30 Gy\u002F10f or 20 Gy\u002F5f) or SBRT (20-40 Gy\u002F1-6f, with ≤ 5 brain metastases and a maximum diameter of ≤ 5cm per lesion); 3. Expected survival of ≥ 3 months; 4. Having sufficient cognitive and understanding abilities, able to cooperate with scale assessments, and able to sign a written informed consent form (ICF); 5. Baseline neurological symptoms are stable (no need for emergency surgical decompression), and if surgery\u002Fradiotherapy has been performed, the following conditions must be met: postoperative\u002Fradiotherapy interval ≥ 4 weeks; 6. Baseline blood glucose\u002Fmetabolism is controllable (e.g., HbA1c ≤ 8.0% in diabetes patients;If HbA1c is high, endocrinology evaluation is required and written permission for enrollment is granted.\n\nExclusion Criteria:\n\n* 1\\. Immediate surgical decompression is required, or there may be progressive cerebral herniation, intracranial pressure crisis, or life-threatening intracranial space occupying lesions present; 2. Has received systemic corticosteroid treatment within 7 days prior to the start of the study medication (such as due to the treatment of systemic lupus erythematosus, bronchial asthma, etc.); 3. Recent cranial surgery or radiation therapy (\\\u003C4 weeks); 4. Individuals with contraindications to glucocorticoids or severe immunosuppression; 5. Suffering from serious basic diseases such as uncontrolled hypertension and diabetes (HbA1c\\>8%), untreated mental illness, active gastric ulcer, heart failure (NYHA III-IV grade), etc; 6. Pregnant\u002Flactating women; 7. Unable to complete the primary assessment scale (severe cognitive\u002Fbehavioral impairment) or unable to sustain Follow up period (e.g. no fixed address, difficult to ensure follow-up); 8. Participated in other intervention therapy trials within the past 4 weeks (which may affect the evaluation results), or is currently receiving drugs that may have serious drug interactions with the investigational drug; 9. Other serious systemic diseases or unsuitability.",{"count":48,"type":20},400,[50,51],"PHASE2","PHASE3","This study is a multicenter, open label, randomized controlled, adaptive phase II\u002FIII seamless design clinical trial aimed at comparing the efficacy and safety of methylprednisolone (MP) and dexamethasone (DEX) in the treatment of peritumoral edema in patients with brain metastases during radiotherapy. The research plan includes brain metastasis patients aged 18-75 years, with KPS scores of 40-80, who plan to undergo whole brain radiotherapy or stereotactic radiotherapy. They will be randomly divided into MP group (40-60 mg\u002Fday) or DEX group (8-12 mg\u002Fday) in a 1:1 ratio, and medication will be continued until the end of radiotherapy, followed by gradual reduction and cessation within one week. The study is divided into two stages: the first stage (stage II exploration) includes 120 cases to preliminarily evaluate the efficacy and safety, and provide a basis for re estimating the sample size in the second stage; The second stage (Phase III confirmation) will expand the sample size based on the results after analysis during the transition period, with a total sample size of no more than 400 cases. The primary endpoint was the change in KPS score and the incidence of grade ≥ 2 hormone related adverse reactions within one week after radiotherapy. Secondary endpoints include cerebral edema index, cognitive function, quality of life, radiotherapy interruption rate, neurotoxicity, survival, and serum biomarkers (IL-6, S100B). The study is supervised by an independent data security monitoring committee and uses statistical methods such as stratified block randomization and mixed effects models to ensure the scientific and ethical compliance of the data. This study is expected to provide high-level evidence-based basis for hormone selection during the perioperative radiotherapy period for patients with brain metastases, and optimize clinical practice.",[54],"Brain Metastases From Solid Tumors",[56,57,58,59,60,61],"Brain metastases","Methylprednisolone","Dexamethasone","Peritumoral edema","Karnofsky performance status score","Biomarkers","NOT_YET_RECRUITING","2026-04-14",{"date":65,"type":31},"2026-04-21",{"date":67,"type":20},"2026-04-15",{"date":69,"type":20},"2028-06-30",{"name":37,"class":38},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":39},"100585684","topical-diclofenac-for-prevention-of-radiation-induced-dermatitis-100585684","NCT06905561","Topical Diclofenac for Prevention of Radiation-induced Dermatitis","Topical Diclofenac for Prevention of Radiation-induced Dermatitis: A Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male and female which are 18 years of age or older\n2. Performance status \\\u003C 2\n3. Epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinus and salivary glands or breast cancer, planned to receive a total dose of at least 50 Gy\n4. The RTOG radiation dermatitis rating should be equal to 0 and the skin nutrition should be good\n5. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g\u002FL, b. WBC ≥3×10\\^9\u002FL c. ANC≥1.5×10\\^9\u002FL, d. PLT ≥100×10\\^9\u002FL; (2) Biochemical examination must meet the following standards: a. BIL\\\u003C1.5 times the upper limit of normal value (ULN), b. ALT and AST\\\u003C2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous creatinine clearance rate\\>60ml\u002Fmin (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range.\n6. Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. A known history of intolerance or allergy to any component of the investigational product;\n3. severe cardiopulmonary disease (such as unstable angina attacks, grade II cardiac insufficiency, acute myocardial infarction, acute episodes of chronic obstructive pulmonary disease, pulmonary heart disease);\n4. The acute phase is accompanied by inflammatory skin diseases, such as atopic dermatitis, contact dermatitis, psoriasis, lichen planus, pityriasis rosea.\n5. Systemic diseases known to delay the skin healing process, such as diabetes or severe kidney failure;\n6. Skin rupture caused by malignant tumors.",{"count":79,"type":20},156,[23],"Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. The Diclofenac is a COX-2 inhibitor and Nonsteroidal anti-inflammatory drugs whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Diclofenac sodium gel as a prophylactic method against the development of RID.",[83,84],"Head and Neck Tumor","Breast Cancer",[86,87,88,89,90],"Topical Diclofenac","Radiation-induced dermatitis","Prevention","Head and Neck tumor","Brest Cancer","2026-03-30",{"date":93,"type":31},"2026-04-03",{"date":95,"type":31},"2025-02-13",{"date":97,"type":20},"2026-08-31",{"name":37,"class":38},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":37,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":119,"locationsCount":39},"100556943","precision-radiotherapy-for-tumours-using-magnetic-resonance-guided-linear-accelerator-mr-linac-100556943","NCT06531681","Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)","Inclusion Criteria:\n\n* Patients are undergoing or have undergone imaging or treatment at the MR linac;\n* Age 18-75 years, male or female;\n* ECOG score 0-2, life expectancy \\> 6 months;\n* Patients provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI;\n* The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy;\n* Acute inflammatory disease requiring systemic therapy;\n* The presence of active infectious disease;\n* Pregnant women, nursing mothers, and patients planning to have children during the study period.",{"count":106,"type":20},3000,"OBSERVATIONAL","Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.",[110,111,112,113],"Overall Response Rate","Oncology","Radiation Toxicity","Quality of Life","2025-02-11",{"date":95,"type":31},{"date":117,"type":31},"2023-08-19",{"date":35,"type":20},{"name":37,"class":38},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":39},"100577282","hypofractionated-radiotherapy-for-nasopharyngeal-carcinoma-100577282","NCT06796270","Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma","Efficacy and Safety of Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 years, male or female；\n2. Performance status ≤ 2 ;\n3. Nasopharyngeal cancer patients diagnosed by pathology (including histology or cytology) , of nasopharyngeal non-keratonic carcinoma (differentiated or undifferentiated, whether TNM staging);\n4. Have at least one evaluable lesion (according to Recist1.1 criteria)\n5. Expected survival ≥6 months.\n6. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g\u002FL, b. WBC ≥3×10\\^9\u002FL c. ANC≥1.5×10\\^9\u002FL, d. PLT ≥100×10\\^9\u002FL; (2) Biochemical examination must meet the following standards: a. BIL\\\u003C1.5 times the upper limit of normal value (ULN), b. ALT and AST\\\u003C2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous creatinine clearance rate\\>60ml\u002Fmin (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range.\n7. Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. As determined by the investigators, there were severe comorbidities that could not tolerate or complete radiation therapy.\n3. There are contraindications in MRI;\n4. Second primary malignancy exists;\n5. Patients with severe complications,such as hypertension, coronary heart disease,mental disease or patients who had any allergies before;\n6. Received any other research in the past 4 weeks before enrollment.",{"count":128,"type":20},24,[23],"The purpose of this study was to evaluate the efficacy and safety of large fractionation radiotherapy in nasopharyngeal carcinoma patients, and to analyze whether Hypofractionated radiotherapy is not inferior to conventional radiotherapy.",[132],"Nasopharyngeal Carcinoma (NPC)",[132,134],"Hypofractionated radiotherapy","2025-01-21",{"date":137,"type":31},"2025-01-28",{"date":139,"type":20},"2026-02-20",{"date":35,"type":20},{"name":37,"class":38},""]